Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,048.42 -23.21 (-0.46%) Dow
38,085.80 -375.12 (-0.98%) Nasdaq
15,611.76 -100.99 (-0.64%) Bitcoin USD
64,297.69 -277.33 (-0.43%) CMC Crypto 200
1,387.16 +4.59 (+0.33%)
OncoCyte Corporation (OCX)
After hours:
| Previous close | 2.4600 |
| Open | 2.4500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.3501 - 2.4599 |
| 52-week range | 2.0800 - 6.2000 |
| Volume | |
| Avg. volume | 57,132 |
| Market cap | 32.545M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.3700 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.06 |
GlobeNewswireOncocyte Reports Full Year 2023 Financial Results
Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP$15.8 million in gross proceeds received from private placement offering$4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, res
- GlobeNewswire
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per
- GlobeNewswire
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c
